HLB Pharmaceutical Co (047920.KQ) Stock Price
HLB Pharmaceutical Co Price
Revenue has compounded at 22.5% per year over the past 13 years to 205.58 B KRW. Earnings per share have declined at 0.5% per year over the last 13 years. HLB Pharmaceutical Co's net margin stands at 2.2%, up from -21.0% several years earlier.
HLB Pharmaceutical Co stock price
HLB Pharmaceutical Co business model & stock analysis
Frequently asked questions about HLB Pharmaceutical Co
Converted at the current exchange rate, the HLB Pharmaceutical Co share trades at 7.96 EUR (11,940.00 KRW).
The revenue cannot currently be calculated for HLB Pharmaceutical Co.
The profit cannot currently be calculated for HLB Pharmaceutical Co.
The P/E ratio cannot be calculated for HLB Pharmaceutical Co at the moment.
The P/S cannot be calculated for HLB Pharmaceutical Co currently.
The Eulerpool Quality Score for HLB Pharmaceutical Co is 5/10.
The ISIN of HLB Pharmaceutical Co is KR7047920004. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The ticker of HLB Pharmaceutical Co is 047920.KQ. The ticker symbol is used to trade HLB Pharmaceutical Co shares on the stock exchange.
HLB Pharmaceutical Co stock
HLB Pharmaceutical Co Peer Group
HLB Pharmaceutical Co FIGI
All fundamentals and in-depth analysis of HLB Pharmaceutical Co
Our stock analysis for HLB Pharmaceutical Co stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of HLB Pharmaceutical Co. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.